Nanoform Finland Plc
The answer first
Does Nanoform Finland beat the market?
No, Nanoform Finland has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 20% of Nordic stocks
- Quality77
- Value11
- Trend17
No. 130 of 195 in healthcare
Max for seven days
Follow Nanoform Finland with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Nanoform Finland
Your first answer is free, no account needed.
Do you own Nanoform Finland, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Nanoform Finland and a few more. Free, no card.
Super Stock+46.4%In short
- Nanoform Finland has fallen 18.5% over the past year, including dividends.
- Overall, Nanoform Finland ranks better than 20% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 86.5%. The price is 91.1% below its peak now.
What do analysts think of Nanoform Finland?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 20% of Nordic stocks.
No. 130 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 62 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.30
- Asset turnoverSales divided by everything the company owns0.08
- Return on equityProfit divided by equity−37.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 131 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.7
- P/SPrice divided by sales15.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 132 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−22.1%
- 6 months−16.0%
- 9 months+3.1%
- 12 months−18.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Nanoform Finland
2 funds we follow own Nanoform Finland. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Nanoform Finland
Nanoform Finland Plc is a company in healthcare, listed on Nasdaq Helsinki. By market value, Nanoform Finland is number 8 of 16 companies in healthcare on Nasdaq Helsinki. Nanoform Finland has not paid a dividend in the past twelve months. Of the three measures in the ranking, Nanoform Finland is strongest on quality, better than 77% of Nordic stocks. The share trades in EUR. It has around 110 employees.
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.


See the full analysis of Nanoform Finland.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card